Stay updated with breaking news from Between Sept. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
1. The semaglutide 50 mg group saw a 15.1% reduction in body weight at 68 weeks compared to 2.4% in the placebo group. 2. Any-grade adverse events were more common among the semaglutide group with the most common being mild-to-moderate severity gastrointestinal symptoms. Evidence Rating Level: 1 (Excellent) Study Rundown: Patients with overweight or obese
1. Median overall survival in the atezolizumab group was 10.3 months versus 9.2 months in the chemotherapy group. 2. Patients assigned to atezolizumab had fewer treatment-related adverse events and treatment-related deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: Prior first-line trials in advanced non-small-cell lung cancer (NSCLC) lacked representation for older or patients with reduced fitness. Data
1. Patients assigned to orforglipron experienced significant reductions in HbA1c, and body weight compared to other groups. 2. The majority of treatment-related adverse events were mild-to-moderate in nature. Evidence Rating Level: 1 (Excellent) Study Rundown: Glucagon-like peptide (GLP-1) receptor agonists are emerging as first-line therapies for the management of type 2 diabetes (T2D). Currently, semaglutide
1. Median overall survival in the atezolizumab group was 10.3 months versus 9.2 months in the chemotherapy group. 2. Patients assigned to atezolizumab had fewer treatment-related adverse events and treatment-related deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: Prior first-line trials in advanced non-small-cell lung cancer (NSCLC) lacked representation for older or patients with reduced
1. Target refractive outcome was achieved in 97% of ISBCS and 98% of DSBCS patients. 2. Societal costs for ISBCS were $507 (€403) lower, on average, compared to DSBCS. Evidence Rating Level: 1 (Excellent) Study Rundown: Cataract surgery accounts for a large proportion of age-related visual surgeries worldwide. Delayed sequential bilateral cataract surgery (DSBCS) is